Portugal - portugisiska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

teva b.v. - lenalidomida - cápsula - 20 mg - cloridrato de lenalidomida hidratado 24.2 mg - lenalidomide - genérico - duração do tratamento: longa duração

Portugal - portugisiska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

teva b.v. - lenalidomida - cápsula - 2.5 mg - cloridrato de lenalidomida hidratado 3.025 mg - lenalidomide - genérico - duração do tratamento: longa duração

Portugal - portugisiska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

teva b.v. - lenalidomida - cápsula - 5 mg - cloridrato de lenalidomida hidratado 6.05 mg - lenalidomide - genérico - duração do tratamento: longa duração

Portugal - portugisiska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

teva b.v. - lenalidomida - cápsula - 15 mg - cloridrato de lenalidomida hidratado 18.15 mg - lenalidomide - genérico - duração do tratamento: longa duração

Portugal - portugisiska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

teva b.v. - lenalidomida - cápsula - 10 mg - cloridrato de lenalidomida hidratado 12.1 mg - lenalidomide - genérico - duração do tratamento: longa duração

Portugal - portugisiska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

teva b.v. - lenalidomida - cápsula - 25 mg - cloridrato de lenalidomida hidratado 30.25 mg - lenalidomide - genérico - duração do tratamento: longa duração

Portugal - portugisiska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

teva b.v. - lenalidomida - cápsula - 10 mg - cloridrato de lenalidomida hidratado 12.1 mg - lenalidomide - genérico - duração do tratamento: longa duração

Portugal - portugisiska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

teva b.v. - lenalidomida - cápsula - 7.5 mg - cloridrato de lenalidomida hidratado 9.075 mg - lenalidomide - genérico - duração do tratamento: longa duração

Europeiska unionen - portugisiska - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - imunossupressores - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) é indicado para o tratamento de pacientes adultos não tratados previamente com mieloma múltiplo que não são elegíveis para transplante. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 e 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) é indicado para o tratamento de pacientes adultos não tratados previamente com mieloma múltiplo que não são elegíveis para transplante. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 e 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Europeiska unionen - portugisiska - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - imunossupressores - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) é indicado para o tratamento de pacientes adultos não tratados previamente com mieloma múltiplo que não são elegíveis para transplante. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) é indicado para o tratamento de pacientes adultos não tratados previamente com mieloma múltiplo que não são elegíveis para transplante. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).